BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
Volume 0.09M
Average 0.07M
Returns on capital
BioStem Technologies, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.8%
avg 89.5%
ROIC
-1.6%
avg 2032.4%
ROA
-13.2%
avg -98.0%
Analysis
ROIC is currently the strongest return metric at -1.6% versus its period average of 2032.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jason Matuszewski | Chief Executive Officer, President, Secretary & Chairman | USD 900K | 39 | 99.90K | 0.59% |
Andrew Vanvurst | Chief Operating Officer & Director | USD 630K | 34 | — | — |
Michael Fortunato | Chief Accounting Officer | USD 506.25K | 58 | — | — |
Brandon Poe | Chief Financial Officer | USD 330.43K | 56 | 6.78K | 0.04% |
Barry J. Hassett | Chief Commercial Officer | — | 59 | — | — |
Noah Agron | Vice President of Corporate Finance & Strategy | — | — | — | — |
Katherine Gorrell | Chief Legal & Compliance Officer | — | 49 | 0 | <0.01% |
David Woynarowski | Chief Medical Officer | — | — | — | — |
Jeff Humke | Vice President of Human Resources | — | — | — | — |
Larry Jones | Chief Revenue Officer | — | — | — | — |
Irmgard Huber | International Medical Advisor & Interim Chief Medical Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Sep 19, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +90.4% | +19.2% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +90.4% over three years. Forward estimates point to Revenue at +19.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does BioStem Technologies, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
No competitor data available.
Questions
Management questions
Common questions about BSEM's management, answered from reported figures.
Who manages BSEM?
BioStem Technologies, Inc. (BSEM) lists 11 active executives. The top listed executive is Barry J. Hassett, Chief Commercial Officer.
Are BSEM insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Continue the stock analysis
Jump to another research area for this company.